X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
CAN-2409 is an investigational off-the-shelf replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene, in combination with valacyclovir is being investigated for the treatment pancreatic cancer.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
CAN-2409 (aglatimagene besadenovec) is an adenoviral replication-defective engineered gene construct encoding the thymidine kinase gene. It is being evaluated in combination with valacyclovir for the treatment of borderline resectable pancreatic ductal adenocarcinoma.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
IMC-2 (combination of valacyclovir and celecoxib) is being evaluated in phase 2 clinical trials as a potential treatment for managing the fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
IMC-2 (combination of valacyclovir + celecoxib) is being evaluated in phase 2 clinical trials as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection (PASC) or Long Covid.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
HY-029 (valaciclovir) is a viral dna polymerase inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of Herpes Simplex Infections.
Lead Product(s): Valacyclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: HY-029
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2023
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. It has received fast track designation for NSCLC in combination with pembrolizumab.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
The Company has initiated the 10-day termination process under the Sales Agreement and is focusing its attention on short-to-medium term operational priorities, including assessment of IMC-2 (fixed combination of valacyclovir and celecoxib) in Long-COVID.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination September 18, 2023
Details:
IMC-2 is a combination of valacyclovir, which inhibits viral DNA polymerase and celecoxib, which is COX-2 inhibitor, as a potential treatment for managing fatigue, sleep, attention, pain, autonomic function and anxiety associated with post-acute sequelae of COVID-19.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. It has received fast track designation for NSCLC in combination with pembrolizumab.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
IMC-2 is a combination of valacyclovir, which inhibits viral DNA polymerase and celecoxib, which is COX-2 inhibitor, as a potential treatment for managing fatigue, sleep, attention, pain, autonomic function and anxiety associated with post-acute sequelae of COVID-19.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
CAN-2409 (aglatimagene besadenovec) is an oncolytic viral immunotherapy that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. Data from the phase 2 trial of CAN-2409 in non-small cell lung cancer shows disease control rate of 77 percent in patients.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
CAN-2409, Candel’s lead viral immunotherapy in development, in combination with nivolumab and standard of care treatment in patients with high-grade glioma.
Lead Product(s): Aglatimagene Besadenovec,Nivolumab,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
CAN-2409 (aglatimagene besadenovec) is genetically modified adenovirus that is designed to encode HSV-tk gene, an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills infected and nearby cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir,Temozolomide
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
IMC-2 (valacyclovir + celecoxib), to treat the symptoms associated with Long-COVID, including fatigue, pain, sleep disruption, anxiety, depression and cognitive function and overall health improvement.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
CAN-2409 (aglatimagene besadenovec), Candel’s most advanced oncolytic viral immunotherapy candidate, is a replication-deficient adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Collaboration may identify early markers of response and inform patient selection for treatment with CAN-2409 with immune checkpoint inhibitor after inadequate tumor response to initial checkpoint inhibitor therapy.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Candel Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2021
Details:
The clinical trial is evaluating CAN-2409 treatment in combination with valacyclovir added to upfront standard of care external beam radiation therapy for patients with localized prostate cancer compared to standard of care radiation therapy alone.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
CAN-2409 (international non-proprietary name: aglatimagene besadenovec) is an adenovirus-based replication-deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $72.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2021
Details:
CAN-2409, previously known as gene-mediated cytotoxic immunotherapy (GMCI™), Candel’s most advanced oncolytic viral immunotherapy candidate, is a replication-deficient adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir,Temozolomide
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
